Naveen Pemmaraju, Professor in the Department of Leukemia at UT MD Anderson Cancer Center, shared on LinkedIn:
“I was thrilled to be able to present, as invited faculty speaker, on Clinical Updates in BPDCN for 2026 at the MD Education Acute Leukemia meeting in La Jolla CA this week !
Our international BPDCN field is truly ‘rapidly growing’ with unmistakable momentum. New exciting progress and novel research on behalf of our patients and families and caregivers facing BPDCN, with our groups around the world leading together and highlight recent approval of PVEK and recently published TAG/AZA/VEN in Blood Journals Portfolio – special shout out to all of our teams, advocates, collaborators, funding and sponsor sources, supporters for Rare Disease in BPDCN and MPNSM research and joining us in our movement for patient-centered approaches in rare and ultra-rare blood cancers!”
Other articles about BPDCN on OncoDaily.